Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 4,731 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo capsules Clear all
Terminated Early Phase 1 Interventional

Vitamin D and Cocaine Administration

NCT04826133
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Calcitriol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
30 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

NCT04223349
View directory record Official record
Conditions
Healthy
Interventions
JNJ-70033093, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects

NCT04508179
View directory record Official record
Conditions
Solid Tumor
Interventions
7HP349 Single Ascending Dose, 7HP349 Multiple Ascending Dose, Placebo Single Ascending Dose, Placebo Multiple Ascending Dose, 7HP349 Food Effect
Drug
Lead sponsor
7 Hills Pharma, LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism

NCT02901041
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Zonisamide, Take Control, Placebo (for Zonisamide)
Drug · Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
21 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Racial and Aging Effects of Acute Antioxidant Supplementation

NCT02157207
View directory record Official record
Conditions
Healthy
Interventions
Antioxidant, Placebo
Dietary Supplement · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Prazosin for Agitation in Alzheimer's Disease

NCT03710642
View directory record Official record
Conditions
Alzheimer's Disease, Disruptive Behavior
Interventions
Prazosin, Placebo oral capsule
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Sun City, Arizona • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

N-Acetyl Cysteine in Trichotillomania

NCT00354770
View directory record Official record
Conditions
Trichotillomania
Interventions
Placebo, N-Acetyl Cysteine
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 18, 2026, 9:24 AM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

NCT00455429
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, JNJ-26113100 (50 mg) once daily, JNJ-26113100 (100 mg) once daily, JNJ-26113100 (100 mg) twice daily, JNJ-26113100 (250 mg) twice daily
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Escalating Study of DAS181 in Adults

NCT00527865
View directory record Official record
Conditions
Influenza
Interventions
DAS181, Placebo
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2009 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Study of BHV-4157 in Alzheimer's Disease

NCT03605667
View directory record Official record
Conditions
Alzheimer Disease
Interventions
troriluzole, Placebo oral capsule
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

NCT01628393
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ozanimod, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Berkeley, California • Fresno, California • Sacramento, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 18, 2026, 9:24 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

NCT04137107
View directory record Official record
Conditions
Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Interventions
Oxaliplatin, Duloxetine Hydrochloride, Duloxetine, Quality-of-Life Assessment, Questionnaire Administration, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
792
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 525 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen

NCT00638807
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Celecoxib, Placebo
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
33
States / cities
Birmingham, Alabama • Buena Park, California • Denver, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Zinc to Treat Tinnitus in the Elderly

NCT00683644
View directory record Official record
Conditions
Tinnitus
Interventions
Zinc, Placebo oral capsule
Drug
Lead sponsor
University of Iowa
Other
Eligibility
60 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)

NCT02840799
View directory record Official record
Conditions
Heart Failure
Interventions
Potassium Nitrate (KNO3), Potassium Chloride (KCl)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Evanston, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

Study of Diclofenac Capsules to Treat Osteoarthritis Pain

NCT01461369
View directory record Official record
Conditions
Osteoarthritis
Interventions
Diclofenac, Placebo
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
40 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

DAW1033B2 in Obstructive Sleep Apnea

NCT03426631
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
Placebo oral capsule, DAW1033B2 oral capsule
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

NCT01854645
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
2,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
121
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730

NCT03054194
View directory record Official record
Conditions
Healthy Participants
Interventions
E2730, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Not applicable Interventional Results available

Effects of Sulfasalazine on BOLD Response to Alcohol Cues

NCT01312129
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Sulfasalazine, Placebo
Drug
Lead sponsor
The Mind Research Network
Other
Eligibility
21 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Functional Dyspepsia Treatment Trial

NCT00248651
View directory record Official record
Conditions
Dyspepsia and Other Specified Disorders of Function of Stomach
Interventions
Amitriptyline, Escitalopram, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 18, 2026, 9:24 AM EDT
Recruiting Phase 2Phase 3 Interventional

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

NCT07284472
View directory record Official record
Conditions
Agitation Associated With Alzheimer's Disease Dementia
Interventions
EXV-802, Placebo, EXV-801
Drug
Lead sponsor
Exciva GmbH
Industry
Eligibility
55 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Murrieta, California • Indianapolis, Indiana • Flowood, Mississippi + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

NCT06673238
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-722, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Cypress, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 18, 2026, 9:24 AM EDT
Completed Phase 4 Interventional Results available

A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD

NCT01749215
View directory record Official record
Conditions
Alcohol Dependence, Posttraumatic Stress Disorder (PTSD)
Interventions
Topiramate, placebo, Medical Management
Drug · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 18, 2026, 9:24 AM EDT